Charles River Laboratories Intl (CRL) Stock Price, Quote & News

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of serv...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 781 222 6000

Website: www.criver.com

Address:

251 Ballardvale Street, Wilmington, United States

smartkarma Aug. 25 at 6:03 AM

$CRL | Charles River Laboratories: Initiation of Coverage- Leveraging Regulatory Wins – Will Flexibility Cement Its Market Leadership? "Charles River Laboratories delivered a mixed financial performance in the second quarter of 2025, presenting some positive aspects alongside key..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/charles-river-laboratories-initiation-of-coverage-leveraging-regulatory-wins-will-flexibility-cement-its-market-leadership

0 · Reply

StockAutoPro Aug. 24 at 11:14 PM

$CRL: Buy target $159.84 Sell target $169.93 Strong earnings report suggests potential for continued growth in leading CRL sector company.

0 · Reply

StockAutoPro Aug. 24 at 3:46 PM

$CRL: Buy target $159.84 Sell target $169.93 Strong earnings growth potential in the clinical research sector signals a bullish outlook.

0 · Reply

GhostVertex Aug. 23 at 10:16 AM

$CRL Charles River Laboratories International Inc is facing biopharma funding environment challenges

0 · Reply

RunnerSignals Aug. 23 at 5:53 AM

$BCPC $CFR $CNQ $CRL $EFX all pushed above their 200DMA today. Some steady, some gaining steam worth watching if momentum holds https://stocksrunner.com/news/2025-08-22-advanced-technical-analysis-for-stock-trading-strategies

0 · Reply

CycleTrade Aug. 22 at 7:12 PM

$CRL Charles Iver Labs support at 100EMA and set for swing https://www.tradingview.com/x/tU7nxO7n/

0 · Reply

StockAutoPro Aug. 21 at 2:41 PM

$CRL: Buy target $157.58 Sell target $167.56 Expect increased volatility in the clinical research sector due to pending healthcare policy changes.

0 · Reply

StockAutoPro Aug. 13 at 11:29 PM

$CRL: Buy target $153.0 Sell target $162.75 Consider investing in this leading contract research organization, showing consistent growth and strong future prospects.

0 · Reply

StockAutoPro Aug. 11 at 8:37 PM

$CRL: Buy target $146.44 Sell target $155.86 Rising demand for telehealth services could boost this leading digital healthcare provider's stock value.

0 · Reply

JarvisFlow Aug. 8 at 12:31 PM

Evercore ISI Group updates rating for Charles River ( $CRL ) to Outperform, target set at 180 → 190.

0 · Reply

Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 12:50 PM EDT - 18 days ago

Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

Aug 6, 2025, 12:47 PM EDT - 18 days ago

Charles River: Margin Fears Outweigh Solid Q2

Aug 6, 2025, 7:55 AM EDT - 19 days ago

Charles River raises profit forecast on growing demand for drug development services

Aug 6, 2025, 7:00 AM EDT - 19 days ago

Charles River Laboratories Announces Second-Quarter 2025 Results

Jul 22, 2025, 8:00 AM EDT - 4 weeks ago

Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development

Jul 15, 2025, 8:00 AM EDT - 5 weeks ago

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

Jun 16, 2025, 8:00 AM EDT - 2 months ago

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

Jun 2, 2025, 8:00 AM EDT - 3 months ago

Charles River Laboratories to Present at William Blair and Jefferies Conferences

May 28, 2025, 8:00 AM EDT - 3 months ago

Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research

May 13, 2025, 8:00 AM EDT - 3 months ago

Charles River Laboratories to Present at Bank of America Health Care Conference

May 10, 2025, 8:49 AM EDT - 3 months ago

Activist Elliott reaches key agreement with Charles River. Here are three ways to create value

May 7, 2025, 5:31 PM EDT - 3 months ago

S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments

May 7, 2025, 2:46 PM EDT - 3 months ago

Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript

May 7, 2025, 12:39 PM EDT - 3 months ago

Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization

May 7, 2025, 12:17 PM EDT - 3 months ago

Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help.

May 7, 2025, 11:56 AM EDT - 3 months ago

Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More

DIS SMCI

May 7, 2025, 7:35 AM EDT - 3 months ago

Charles River to add new directors, review business in agreement with Elliott

May 7, 2025, 7:01 AM EDT - 3 months ago

Charles River Laboratories Announces First-Quarter 2025 Results

May 7, 2025, 7:00 AM EDT - 3 months ago

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

May 7, 2025, 6:08 AM EDT - 3 months ago

Exclusive: Charles River agrees with Elliott to add new directors, review business

Apr 29, 2025, 8:00 AM EDT - 4 months ago

Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort

Apr 22, 2025, 8:00 AM EDT - 4 months ago

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development

Apr 15, 2025, 4:30 PM EDT - 4 months ago

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

Apr 11, 2025, 10:44 AM EDT - 4 months ago

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

CERT SLP

Mar 25, 2025, 8:00 AM EDT - 5 months ago

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Mar 11, 2025, 8:00 AM EDT - 5 months ago

Charles River Laboratories to Present at Barclays Global Healthcare Conference

Mar 4, 2025, 4:05 AM EST - 6 months ago

FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility

Feb 25, 2025, 8:00 AM EST - 6 months ago

Charles River Announces Agreement with Singapore General Hospital

Feb 19, 2025, 4:58 PM EST - 6 months ago

Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance

Feb 19, 2025, 3:03 PM EST - 6 months ago

Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 8:11 AM EST - 6 months ago

Charles River beats quarterly estimates on stable demand for drug development services

Feb 19, 2025, 7:00 AM EST - 6 months ago

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

Feb 11, 2025, 8:00 AM EST - 6 months ago

Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions

Jan 28, 2025, 4:30 PM EST - 7 months ago

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call

Jan 21, 2025, 8:00 AM EST - 7 months ago

Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences

Jan 16, 2025, 8:00 AM EST - 7 months ago

Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

Jan 13, 2025, 8:00 AM EST - 8 months ago

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:00 AM EST - 8 months ago

Deciphex Secures $32.3M Series C to Address Global Pathology Shortage

Dec 20, 2024, 7:51 AM EST - 8 months ago

Tax-related selling is hitting these 7 stocks — but their loss could be your gain

AVNW CVS DLHC FL VAL

Dec 5, 2024, 8:00 AM EST - 9 months ago

Charles River Introduces Global Biotech Incubator Program

Dec 2, 2024, 8:00 AM EST - 9 months ago

Charles River Laboratories to Present at Evercore ISI Investor Conference

Nov 11, 2024, 8:00 AM EST - 10 months ago

Charles River Laboratories to Present at UBS and Jefferies Conferences

Nov 6, 2024, 6:51 PM EST - 10 months ago

Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:30 AM EST - 10 months ago

Charles River Laboratories raises annual profit forecast on stabilizing biotech demand

Nov 6, 2024, 7:00 AM EST - 10 months ago

Charles River Laboratories Announces Third-Quarter 2024 Results

Oct 17, 2024, 8:00 AM EDT - 11 months ago

Charles River Launches New Retrogenix® Non-Human Protein Library

Oct 16, 2024, 4:30 PM EDT - 11 months ago

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call

Oct 8, 2024, 11:26 AM EDT - 11 months ago

Operadora de Fondos Banorte Adopts Charles River's Cloud-Based Platform

Oct 3, 2024, 8:00 AM EDT - 11 months ago

Charles River Provides Translational Expertise at Neuroscience 2024

smartkarma Aug. 25 at 6:03 AM

0 · Reply

StockAutoPro Aug. 24 at 11:14 PM

$CRL: Buy target $159.84 Sell target $169.93 Strong earnings report suggests potential for continued growth in leading CRL sector company.

0 · Reply

StockAutoPro Aug. 24 at 3:46 PM

$CRL: Buy target $159.84 Sell target $169.93 Strong earnings growth potential in the clinical research sector signals a bullish outlook.

0 · Reply

GhostVertex Aug. 23 at 10:16 AM

$CRL Charles River Laboratories International Inc is facing biopharma funding environment challenges

0 · Reply

RunnerSignals Aug. 23 at 5:53 AM

0 · Reply

CycleTrade Aug. 22 at 7:12 PM

$CRL Charles Iver Labs support at 100EMA and set for swing https://www.tradingview.com/x/tU7nxO7n/

0 · Reply

StockAutoPro Aug. 21 at 2:41 PM

$CRL: Buy target $157.58 Sell target $167.56 Expect increased volatility in the clinical research sector due to pending healthcare policy changes.

0 · Reply

StockAutoPro Aug. 13 at 11:29 PM

$CRL: Buy target $153.0 Sell target $162.75 Consider investing in this leading contract research organization, showing consistent growth and strong future prospects.

0 · Reply

StockAutoPro Aug. 11 at 8:37 PM

$CRL: Buy target $146.44 Sell target $155.86 Rising demand for telehealth services could boost this leading digital healthcare provider's stock value.

0 · Reply

JarvisFlow Aug. 8 at 12:31 PM

Evercore ISI Group updates rating for Charles River ( $CRL ) to Outperform, target set at 180 → 190.

0 · Reply

JarvisFlow Aug. 7 at 7:10 PM

JP Morgan has updated their rating for Charles River ( $CRL ) to Neutral with a price target of 160.

0 · Reply

JarvisFlow Aug. 7 at 1:12 PM

Barclays updates rating for Charles River ( $CRL ) to Equal-Weight, target set at 155 → 165.

0 · Reply

RaroMalo Aug. 6 at 7:47 PM

$SPY $CC $CRL $LYB companies that make stuff for the real world, not the simulated world are taking a real world beating whereas companies making real products for a simulated world are taking all the real world money.

1 · Reply

ZacksResearch Aug. 6 at 6:13 PM

$CRL beats earnings by 24.8% — what's driving the surge? 🚀 Second-quarter 2025 EPS hit $3.12, with revenues climbing 0.6% to $1.03B, surpassing expectations. Despite an operating margin dip, organic growth in RMS and Manufacturing Solutions segments boosts optimism. Explore the full breakdown here 👉 https://www.zacks.com/stock/news/2672927/crl-stock-gains-on-q2-earnings-and-revenue-beat-raises-25-view?cid=sm-stocktwits-2-2672927-body-6283&ADID=SYND_STOCKTWITS_TWEET_2_2672927_BODY_6283

0 · Reply

YouOnlyLiveTwice Aug. 6 at 1:58 PM

$CRL All the companies in this space will continue to go lower probably for the next 2-3 years

0 · Reply

ZacksResearch Aug. 6 at 1:08 PM

$CRL just delivered a beat-and-raise — and the market’s loving it 🔥 Q2 earnings and revenue topped estimates, and the company raised its 2025 outlook. Shares up 9.3% pre-market. Full breakdown here 👉 https://www.zacks.com/stock/news/2672927/crl-stock-gains-on-q2-earnings-and-revenue-beat-raises-25-view?cid=sm-stocktwits-2-2672927-teaser-6236&ADID=SYND_STOCKTWITS_TWEET_2_2672927_TEASER_6236

0 · Reply

OpenOutcrier Aug. 6 at 12:15 PM

$CRL (+0.9% pre) Charles River Labs Earnings Surge Past Estimates: Key Highlights from Q2 Results and Raised Outlook https://ooc.bz/l/72764

0 · Reply

jaydilks Aug. 3 at 11:35 AM

$DNA People really haven’t discussed we have a new Chief Financial Officer that assumed the role in May after joining Ginkgo a year earlier from a long career at $CRL and with Deloitte. As soon as Steve took over for Mark Dmytruk, Ginkgo Bioworks hired Deloitte to be the new Auditor. One of the biggest complaints and maybe rightfully so, was the previous CFO would have this certain knack for taking perceived good news on the call and turning it into something that was fleeting success and a one-time event. The nerd in me realized he was just covering his butt for the future. The business part of me wanted to figuratively, slap him for opening his mouth and just take a win. So Thursday will be different. One could say it can’t be worse from a Theatrical point of view. Charles River Labs is a tough and Complex business. I could make a case that DNA is an infinitely easier gig just from the scale of operations.

1 · Reply

YouOnlyLiveTwice Jul. 30 at 11:12 PM

$CRL They had their run for a few days now back to their 3 year downtrends This space is very much out of favor. This could last another 3 years ONLY this changes is through consolidation otherwise lower

1 · Reply

ZacksResearch Jul. 30 at 1:31 PM

$CRL set for Q2 earnings — will it beat expectations again? 📈 CRL has an Earnings ESP of +0.11% and a Zacks Rank #3, indicating potential for a beat. Yet, challenges like NIH budget cuts and tariffs could pressure revenues and margins. Discover the full earnings preview here 👉 https://www.zacks.com/stock/news/2638082/charles-river-q2-earnings-preview-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2638082-body-4658&ADID=SYND_STOCKTWITS_TWEET_2_2638082_BODY_4658

0 · Reply

ZacksResearch Jul. 30 at 12:03 PM

$CRL Q2 preview — is the setup bullish or bearish? 🧐 Investors are watching closely as Charles River prepares to report Q2 results — expectations and surprises could swing the stock. Full preview and setup breakdown here 👉 https://www.zacks.com/stock/news/2638082/charles-river-q2-earnings-preview-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2638082-teaser-4651&ADID=SYND_STOCKTWITS_TWEET_2_2638082_TEASER_4651

0 · Reply

ccnau Jul. 24 at 1:47 PM

$CRL up, Chuck

0 · Reply

Market Cap	7.96B
Revenue (ttm)	4.05B
Net Income (ttm)	22.20M
EPS (ttm)	N/A
PE Ratio	14.43
Forward PE	15.14
Profit Margin	0.55%
Debt to Equity Ratio	0.69

Volume	1,254,500
Avg Vol	907,978
Day's Range	N/A - N/A
Shares Out	49.21M
Stochastic %K	82%
Beta	1.48
Analysts	Sell
Price Target	$168.64